This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

InOncology.com

ELCC, GENEVA, 11 - 14 APRIL 2018

Second-line afatinib for patients with locally advanced or metastatic NSCLC harbouring common EGFR mutations: a Phase IV study

Sumitra Thongprasert, Sarayut Geater, Dana Clement, Amr Abdelaziz, Jasmin Reyer-Igama, Dragana Jovanovic, Sheethal Suresh, Agnieszka Cseh, Rabab Gaafar

ELCC_2018 1200.217_poster

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

ErbB family receptors and afatinib mechanism of action video

Rate this

FOR HEALTHCARE PROFESSIONALS ONLY

 

In the European Union, afatinib is approved for use in TKI-naive adults with locally advanced or metastatic NSCLC with activating EGFR mutations and in patients with NSCLC of squamous histology on or after chemotherapy. It is not yet approved in other indications.

 

In Switzerland, Afatinib is approved as monotherapy for patients with non-small cell lung cancer (NSCLC, stage IIIb/IV) with activating mutations of EGFR (exon 19 deletions or exon 21 L858R substitutions), not previously treated with EGFR TKIs. It is also indicated for the treatment of patients with locally advanced or metastatic squamous cell cancer of the lung whose carcinoma progressed during or after platinum-based chemotherapy and for whom immunotherapy is not suitable.